McKinsey and Company's involvement in boosting OxyContin sales for Purdue Pharma

McKinsey and Company agreed to pay $650 million to settle federal probes into its role in boosting OxyContin sales for Purdue Pharma. The settlement includes a deferred prosecution agreement and a guilty plea from a former senior partner for obstruction of justice. The company also apologized for its actions and agreed to refrain from work involving controlled substances in the future.